Intech Investment Management LLC Makes New Investment in Inogen, Inc. (NASDAQ:INGN)

Intech Investment Management LLC bought a new position in shares of Inogen, Inc. (NASDAQ:INGN) in the 4th quarter, HoldingsChannel.com reports. The institutional investor bought 10,285 shares of the medical technology company’s stock, valued at approximately $94,000.

A number of other large investors have also recently made changes to their positions in the stock. Royce & Associates LP lifted its holdings in Inogen by 499.7% during the 4th quarter. Royce & Associates LP now owns 311,199 shares of the medical technology company’s stock valued at $2,854,000 after buying an additional 259,308 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. increased its position in shares of Inogen by 42.5% during the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 248,822 shares of the medical technology company’s stock worth $2,282,000 after acquiring an additional 74,197 shares during the period. Monaco Asset Management SAM raised its stake in shares of Inogen by 104.0% during the fourth quarter. Monaco Asset Management SAM now owns 76,500 shares of the medical technology company’s stock valued at $702,000 after acquiring an additional 39,000 shares in the last quarter. Bank of New York Mellon Corp boosted its holdings in shares of Inogen by 23.5% in the fourth quarter. Bank of New York Mellon Corp now owns 126,461 shares of the medical technology company’s stock valued at $1,160,000 after purchasing an additional 24,082 shares during the period. Finally, JPMorgan Chase & Co. grew its stake in Inogen by 2.7% in the third quarter. JPMorgan Chase & Co. now owns 896,106 shares of the medical technology company’s stock worth $8,692,000 after purchasing an additional 23,891 shares in the last quarter. 89.94% of the stock is owned by hedge funds and other institutional investors.

Inogen Stock Performance

Shares of INGN opened at $7.14 on Friday. The company has a 50 day moving average price of $9.48 and a 200-day moving average price of $9.58. Inogen, Inc. has a fifty-two week low of $6.14 and a fifty-two week high of $13.33. The stock has a market capitalization of $189.42 million, a PE ratio of -3.17 and a beta of 1.15.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the company. StockNews.com lowered Inogen from a “buy” rating to a “hold” rating in a research report on Wednesday, February 26th. Needham & Company LLC restated a “hold” rating on shares of Inogen in a research note on Wednesday, February 26th.

Inogen Company Profile

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.